Industry News

• Blood test may identify gestational diabetes risk in first trimester  A blood test conducted as early as the 10th week of pregnancy may help identify women at risk for gestational diabetes, a pregnancy-related condition that poses potentially serious health risks for mothers and infants. The study appears in Scientific Reports.
  August 16, 2018  
• NIH begins clinical trial of live, attenuated Zika vaccine  Vaccinations have begun in a first-in-human trial of an experimental live, attenuated Zika virus vaccine developed by scientists at the NIAID. The trial will enroll a total of 28 healthy, non-pregnant adults ages 18 to 50. NIAID is sponsoring the trial.
  August 16, 2018  
• Inovio treats first patient in immuno-oncology study for advanced bladder cancer  Inovio Pharmaceuticals announced it has dosed its first patient in a Phase 1/2a study designed to evaluate the safety, immunogenicity and clinical efficacy of INO-5401, Inovio’s novel cancer immunotherapy that encodes multiple cancer antigens.
  August 16, 2018  
• AgeX Therapeutics acquires technology to regulate immune tolerance  AgeX Therapeutics, a subsidiary of BioTime, announced it has acquired certain patents and patent applications from Escape Therapeutics relating primarily to the use of the HLA-G gene to suppress rejection of transplanted cells and tissues.
  August 16, 2018  
• Trovagene announces completion of second dosing of patients treated with Onvansertib  Trovagene announced completion of the second dosing cohort of Onvansertib, a first-in-class, 3rd generation, highly-selective oral Polo-like Kinase 1 Inhibitor, in combination with standard-of-care low-dose cytarabine, in its Phase 1b/2 clinical trial in patients with Acute Myeloid Leukemia.
  August 16, 2018  
• Pain Therapeutics announces $11.3 million registered direct offering priced at-the-market  Pain Therapeutics announced that it has entered into definitive agreements with several institutional investors for the purchase of 8,860,778 shares of its common stock, at a purchase price per share of $1.15, for gross proceeds of $10.19 million, in a registered direct offering.
  August 16, 2018  
• Regeneron and Teva announce positive topline phase 3 fasinumab results  Regeneron and Teva announced positive topline results from a Phase 3, randomized, double-blind, placebo-controlled study of fasinumab in patients with chronic pain from osteoarthritis of the knee or hip. At the week 16 primary efficacy analysis, the study met both co-primary endpoints.
  August 16, 2018  
• Summit awarded additional $12 million by BARDA for ridinilazole  Summit Therapeutics announces it has been awarded an additional $12 million under its contract with BARDA. The funds will support the Phase 3 development programme for ridinilazole, the Company's precision new mechanism antibiotic for the treatment of C. difficile infection.
  August 16, 2018  
• Trovagene receives USAN approval for "Onvansertib" as nonproprietary name  Trovagene announced the USAN Council has approved "Onvansertib" (pronounced on-van-ser-tib) as the nonproprietary (generic) name for its drug candidate, PCM-075. Onvansertib is a first-in-class, 3rd generation, highly selective, oral Polo Like Kinase 1 inhibitor designed to inhibit mitosis.
  August 16, 2018  
• CytoDyn announces strong preclinical results using PRO 140 in human colon carcinoma  CytoDyn announces that PRO 140 (leronlimab) has been shown effective at inhibiting the growth of a human colon carcinoma cell line (SW480) in a prominent mouse model. The results were statistically significant and provide the basis for filing an IND application with the FDA for a clinical trial.
  August 15, 2018  

   (next 10 articles)